Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Arena Pharmaceuticals |
---|---|
Information provided by: | Arena Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00828659 |
The purpose of this study is to evaluate the abuse potential of lorcaserin in healthy recreational polydrug users.
Condition | Intervention | Phase |
---|---|---|
Drug Abuse Healthy |
Drug: Placebo Drug: Active Comparator #1 Drug: Active Comparator #2 Drug: Active Comparator #3 Drug: Lorcaserin Dose #1 Drug: Lorcaserin Dose #2 Drug: Lorcaserin Dose #3 |
Phase I |
Study Type: | Interventional |
Study Design: | Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Pharmacodynamics Study |
Official Title: | A Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users |
Estimated Enrollment: | 35 |
Study Start Date: | December 2008 |
Study Completion Date: | April 2009 |
Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Placebo: Placebo Comparator | Drug: Placebo |
Active Comparator #1: Active Comparator | Drug: Active Comparator #1 |
Active Comparator #2: Active Comparator | Drug: Active Comparator #2 |
Active Comparator #3: Active Comparator | Drug: Active Comparator #3 |
Lorcaserin Dose #1: Experimental | Drug: Lorcaserin Dose #1 |
Lorcaserin Dose #2: Experimental | Drug: Lorcaserin Dose #2 |
Lorcaserin Dose #3: Experimental | Drug: Lorcaserin Dose #3 |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
INCLUSION CRITERIA
EXCLUSION CRITERIA A subject will not be considered eligible to participate in this study, if any one of the following exclusion criteria is satisfied:
Responsible Party: | Arena Pharmaceuticals, Inc. ( Christen Anderson, MD, PhD ) |
Study ID Numbers: | APD356-013 |
Study First Received: | January 22, 2009 |
Last Updated: | July 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00828659 History of Changes |
Health Authority: | United States: Food and Drug Administration; Canada: Health Canada |
Abuse potential |
Mental Disorders Substance-Related Disorders Disorders of Environmental Origin Healthy |
Mental Disorders Substance-Related Disorders Disorders of Environmental Origin |